Longitudinal exposure to non‐ HDL ‐C and cardiovascular events, all‐cause mortality in type 2 diabetes: A post hoc analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
Authors' conclusion
Longitudinal non-HDL-C exposure showed associations with both MACEs and mortality, independent of baseline non-HDL-C, underscoring the need for sustained and stable non-HDL-C control over time.
Study context
- Population
- Patients with T2D on lipid-lowering therapy in the ACCORD Lipid trial, with non-HDL-C measured at baseline and four subsequent visits over 24 months
- Participants
- 4,673 patients
- Comparison
- Highest vs lowest quartile of longitudinal non-HDL-C exposure
- Primary endpoint
- MACE and all-cause mortality
- Follow-up
- Median 7.5 years
Methodological detailspost hoc analysis
- Post hoc analysis
Primary result
As reported in the abstract
MACE
Highest quartile vs Lowest quartileHazard ratio (95% CI)
Cumulative load
1.81(1.41–2.32)
Variability
1.27(1.00–1.60)
Most rapidly increasing slope
1.26(1.02–1.56)
- MACE events
- 695
Further findings
All-cause mortality · median follow-up 7.5 years
- Deaths
- 842
- Association followed a similar pattern as for MACE, except for non-HDL-C slope
Stratified by baseline non-HDL-C
- Cumulative load and variability associated with MACE among baseline non-HDL-C < 130 mg/dL, and with all-cause mortality among baseline ≥130 mg/dL
- No significant associations with slope within strata of baseline non-HDL-C
Original publication
Longitudinal exposure to non‐ HDL ‐C and cardiovascular events, all‐cause mortality in type 2 diabetes: A post hoc analysis of the ACCORD trial. Diabetes Obes Metab. Published 21 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →